RYZ-101 is under clinical development by RayzeBio and currently in Phase III for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Phase III drugs for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how RYZ-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RYZ-101 overview
RYZ-101 is under development for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), extensive stage small cell lung cancer, relapsed and refractory multiple myeloma (MM). The drug candidate is an actinium-225 radiolabeled conjugated synthetic peptide somatostatin analog (SSA) which acts by targeting cell expressing somatostatin receptor 2 (SSTR2). It is administered parenterally and intravenously.
RayzeBio overview
RayzeBio is a biotechnology company that aims to improve clinical benefit by efficiently developing innovative tumor-targeted small-molecule medicines that harness the power of radioisotopes. It is headquartered in San Diego, California, the US.
For a complete picture of RYZ-101’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
